These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: Hepatorenal syndrome: emerging perspectives.
    Author: Epstein M.
    Journal: Semin Nephrol; 1997 Nov; 17(6):563-75. PubMed ID: 9353866.
    Abstract:
    Progressive oliguric renal failure (designated hepatorenal syndrome) commonly complicates the course of patients with advanced hepatic disease. Despite the severe derangement of renal function and ominous prognosis when renal failure develops, minimal and inconsistent pathologic abnormalities of the kidneys are found at autopsy. Furthermore, the kidneys, if transplanted, are capable of normal function, which supports the concept that the renal failure is functional and potentially reversible. In contrast to patients with classical acute renal failure (ATN), hepatorenal syndrome patients manifest characteristic alterations of renal function including (1) relatively hyperosmolar urine; (2) high creatinine urine to plasma (U:P) ratio, and (3) a very low urine sodium concentration (< 10 mEq/L). During the past several years we have witnessed new insights into both the pathophysiology and the therapeutics of this syndrome. The application of new methodology such as tracer kinetics has more rigorously delineated the role of a number of pathogenic mechanisms, including activation of the sympathetic nervous system. The characterization of endothelin and nitric oxide-arginine pathway and their roles in biology and medicine has provided additional new insights with regard to the pathogenesis of hepatorenal syndrome. For example, nitric oxide has been proposed to constitute a mediator of both the hyperdynamic circulation and renal failure. Finally, recently initiated therapeutic approaches lend a note of optimism to the future management of a syndrome that is so often incompatible with recovery. These include the acceptance of orthotopic liver transplantation as definitive treatment for patients with end-stage liver disease and attempts to improve renal function by use of transjugular intrahepatic porto-systemic shunt. Hopefully, ongoing and future clinical trials will establish the precise contribution of each of these treatment modalities and their respective roles in the therapeutic armamentarium.
    [Abstract] [Full Text] [Related] [New Search]